close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NICOX SA

News headline image
Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides First Half 2025 Financial Results
From NICOX SA
Via GlobeNewswire
News headline image
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Shareholder Q&A Webpage Available
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
From NICOX SA
Via GlobeNewswire
News headline image
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
From NICOX SA
Via GlobeNewswire
News headline image
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides Full Year 2024 Financial Results
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream
From NICOX SA
Via GlobeNewswire
News headline image
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
From NICOX SA
Via GlobeNewswire
News headline image
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Approval of ZERVIATE in China
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470
From NICOX SA
Via GlobeNewswire
News headline image
Nicox announces attendance at upcoming conferences
From NICOX SA
Via GlobeNewswire
News headline image
Nicox Provides Second Quarter 2024 Update
From NICOX SA
Via GlobeNewswire
News headline image
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
From NICOX SA
Via GlobeNewswire
News headline image
Nicox: 2024 Ordinary Shareholder Meeting
From NICOX SA
Via GlobeNewswire
News headline image
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
From NICOX SA
Via GlobeNewswire
News headline image
Nicox’s Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024
From NICOX SA
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today